Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442847 | 1.00 | PARP1 (0.34) | PARP1NUDT1PSMD14GRM4KCNMA1 | |
| Potassium Ion SCHEMBL29563578 | 0.91 | PARP1 (0.30) | PARP1 | |
| SCHEMBL2070476 | 0.69 | PSMD14 (0.35) | PARP1NUDT1PSMD14KCNMA1DAO | |
| SCHEMBL2845655 | 0.67 | KDM4E (0.35) | NUDT1CDK2 | |
| SCHEMBL5894475 | 0.62 | LMNA (0.38) | NUDT1PSMD14METAP2METAP1 | |
| SCHEMBL29356921 | 0.61 | ALDH1A1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL30269612 | 0.61 | PSMD14 (0.35) | PARP1NUDT1PSMD14KCNMA1DAO | |
| SCHEMBL2729735 | 0.61 | MMP2 (0.37) | NUDT1PSMD14METAP2METAP1 | |
| SCHEMBL30201375 | 0.61 | NUDT1 (0.40) | PARP1NUDT1PSMD14KCNMA1PDE5A | |
| SCHEMBL5894605 | 0.60 | TDP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624035-B2 | Compounds for targeted protein degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-07 | — | — | US | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| EP-3194396-A1 | DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3186259-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-12 | — | — | US | disclosed |
| WO-2016044120-A1 | DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20120238563-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | CID-NUNEZ JOSE MARIA (ES) | 2012-09-20 | — | — | US | disclosed |
| US-20120035170-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | NUNEZ JOSE MARIA (ES) | 2012-02-09 | — | — | US | disclosed |
| US-8022102-B2 | Unsaturated tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | IRAK4, IRAK1, IRAK2 | PARP1 1854/4885NUDT1 3126/4885PSMD14 1747/4885 |
| US-20120035170-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | HTR2C, HTR2A, HTR1A | PARP1 2590/4885NUDT1 452/4885PSMD14 4246/4885 |
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BRD9, BRWD1, BRD1 | PARP1 1321/4885NUDT1 4697/4885PSMD14 40/4885 |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | PARP1 3730/4885NUDT1 3693/4885PSMD14 3435/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | PARP1 2993/4885NUDT1 369/4885PSMD14 4368/4885 |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | PARP1 176/4885NUDT1 6/4885PSMD14 3690/4885 |
| US-12624035-B2 | Compounds for targeted protein degradation | BRD9, BRD1, BRD3 | PARP1 1247/4885NUDT1 4532/4885PSMD14 24/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | PARP1 1071/4885NUDT1 384/4885PSMD14 2712/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | PARP1 4681/4885NUDT1 2343/4885PSMD14 4319/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | PARP1 449/4885NUDT1 884/4885PSMD14 3794/4885 |
| US-20120238563-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | HTR2C, HTR2A, HTR1A | PARP1 2590/4885NUDT1 452/4885PSMD14 4246/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PARP1 2461/4885NUDT1 4085/4885PSMD14 293/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | PARP1 2068/4885NUDT1 3796/4885PSMD14 2845/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | PARP1 4444/4885NUDT1 4511/4885PSMD14 4268/4885 |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | MLLT1, MEN1, MLLT3 | PARP1 909/4885NUDT1 1706/4885PSMD14 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.